Skip to content

A prospective cohort study to construct a predictive model for the risk of nausea and vomiting associated with tumor treatment

A prospective cohort study to construct a predictive model for the risk of nausea and vomiting associated with tumor treatment

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300073670
Enrollment
Unknown
Registered
2023-07-18
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Case series:None

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age of diagnosis: 18-70 years old; 2. The patient was diagnosed with malignant tumor by histopathology; 3. The patient was born and lived in the People's Republic of China for a long time; 4. Patients need to receive at least one anti-tumor treatment such as surgery, chemotherapy, radiotherapy, targeting, and immunity.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to receive anti-tumor therapy; 2. Patients who cannot cooperate with the evaluation of CTCAE nausea and vomiting; 3. Patients with other factors that may cause nausea and vomiting other than anti-tumor therapy, including: intestinal obstruction, brain metastasis, cranial hypertension, abdominal effusion, gastroparesis, vestibular dysfunction, uremia; 4. In addition to this anti-tumor treatment stage, the patient has a history of malignant tumors in the past, or the patient has received anti-tumor treatment in the past; 5. Other situations assessed by the researchers that may endanger patient safety or compliance, such as serious diseases (including psychiatric diseases) that require timely treatment, serious abnormal test results, and other family or social high-risk risk factors;

Design outcomes

Primary

MeasureTime frame
nausea and vomiting ;

Secondary

MeasureTime frame
Chemotherapy regimen;surgical site;Radiation exposure site;Immunotherapy medication;

Countries

China

Contacts

Public ContactZhang Xiaomin

Peking University Shenzhen Hospital

zhxiaom8@mail2.sysu.edu.cn+86 138 2339 4747

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026